PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
3663268-1	1987	D,L-4-(3,4-Dichloro-benzoylamino)-5-(N-3-methoxypropyl- pentylamino)-5-oxo-pentanoic acid (CR 1505) belongs to a newly discovered class of agents with cholecystokinin (CCK) antagonistic activity.	loxiglumide	0-89	cholecystokinin	Cavia porcellus	151-166	
3663268-1	1987	D,L-4-(3,4-Dichloro-benzoylamino)-5-(N-3-methoxypropyl- pentylamino)-5-oxo-pentanoic acid (CR 1505) belongs to a newly discovered class of agents with cholecystokinin (CCK) antagonistic activity.	loxiglumide	0-89	cholecystokinin	Cavia porcellus	168-171	
9522034-2	1998	Radioligand displacement assay was performed to characterize the selectivity of loxiglumide to CCK-A (cholecystokinin-A) receptor (rat pancreas and bovine gallbladder) and CCK-B/gastrin receptors (guinea pig cerebral cortex and guinea pig gastric parietal cell).	loxiglumide	80-91	cholecystokinin	Cavia porcellus	95-98	
16484960-3	2003	Dexloxiglumide, the active enantiomer of loxiglumide, interacts competitively with CCK1 receptors as determined in preclinical studies, such as specific radioligand binding assays or functional studies on isolated guinea pig gallbladder, where it inhibited smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8), the most prominent active forms of cholecystokinin.	loxiglumide	3-14	cholecystokinin	Cavia porcellus	300-315	
16484960-3	2003	Dexloxiglumide, the active enantiomer of loxiglumide, interacts competitively with CCK1 receptors as determined in preclinical studies, such as specific radioligand binding assays or functional studies on isolated guinea pig gallbladder, where it inhibited smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8), the most prominent active forms of cholecystokinin.	loxiglumide	3-14	cholecystokinin	Cavia porcellus	372-387	
9522034-4	1998	Loxiglumide inhibited 125I-CCK-8 binding to rat pancreatic and bovine gallbladder membranes with IC50 values of 195 and 77.1 nmol/l, respectively.	loxiglumide	0-11	cholecystokinin	Cavia porcellus	27-30	
9522034-5	1998	Loxiglumide also inhibited 125I-CCK-8 binding to guinea pig cerebral cortex membranes and parietal cells with IC50 values of 12363 and 15455 nmol/l, respectively.	loxiglumide	0-11	cholecystokinin	Cavia porcellus	32-35	
9522034-7	1998	These results indicate that the affinity of loxiglumide to CCK-A receptor is at least 63 times greater than that to CCK-B/gastrin receptors.	loxiglumide	44-55	cholecystokinin	Cavia porcellus	59-62	
9522034-8	1998	In vitro functional studies utilizing CCK-induced contractions of the isolated guinea pig gallbladder and ileum further demonstrate that loxiglumide acts as a competitive CCK antagonist with a high affinity to these tissues (gallbladder, pA2:6.71).	loxiglumide	137-148	cholecystokinin	Cavia porcellus	38-41	
9522034-8	1998	In vitro functional studies utilizing CCK-induced contractions of the isolated guinea pig gallbladder and ileum further demonstrate that loxiglumide acts as a competitive CCK antagonist with a high affinity to these tissues (gallbladder, pA2:6.71).	loxiglumide	137-148	cholecystokinin	Cavia porcellus	171-174	
8844481-1	1996	We evaluated the effect of the specific cholecystokinin (CCK) receptor antagonist, loxiglumide, on gallbladder contractile function in guinea pigs.	loxiglumide	83-94	cholecystokinin	Cavia porcellus	57-60	
8844481-6	1996	These results suggest that the disturbed gallbladder contraction is due to the competitive inhibition of CCK by loxiglumide.	loxiglumide	112-123	cholecystokinin	Cavia porcellus	105-108	
8115030-0	1993	Effect of loxiglumide (CR 1505) on CCK-induced contractions and 3H-acetylcholine release from guinea-pig gallbladder.	loxiglumide	10-21	cholecystokinin	Cavia porcellus	35-38	
8115030-5	1993	Loxiglumide, (CR 1505), a newly synthesized nonpeptide CCK-A-receptor antagonist, D.L-(3,4-dichlorbenzoilamino)-5-/N-(3-methoxypropyl)-pentylamin o-5-oxo-pentanoi c acid, antagonized both the ACh-releasing effect of CCK and the contractions in a dose-dependent manner.	loxiglumide	0-11	cholecystokinin	Cavia porcellus	55-58